Skip to main
DYN

Dyne Therapeutics (DYN) Stock Forecast & Price Target

Dyne Therapeutics (DYN) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 50%
Buy 42%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Dyne Therapeutics Inc is experiencing significant growth in operating expenses, reflecting an increase of 36% to $468 million in FY25 compared to FY24, indicating substantial investment in its clinical pipeline. The positive data from z-rostudirsen, demonstrating a statistically significant improvement in muscle content-adjusted dystrophin expression and long-term cardiopulmonary function, reinforces the company’s strong positioning for potential FDA accelerated approval. The pipeline's focus on commercially attractive indications and the anticipated positive trial readout from a competitor suggest further upside potential for Dyne Therapeutics, bolstering a favorable outlook for the stock.

Bears say

Dyne Therapeutics reported a significant net loss of $446 million for the year, equating to an earnings per share (EPS) of ($3.47), which is a slight increase in losses compared to the previous year. The company's challenging outlook is compounded by a series of potential downsides, including concerns over the efficacy of its lead candidate DYNE-101, slower-than-expected clinical trial progress, and potential safety issues with its drug delivery system. Additionally, Dyne's market capitalization of approximately $3 billion reflects investor apprehensions regarding the timeline and viability of its key programs, particularly in the competitive landscape of oligonucleotide therapies.

Dyne Therapeutics (DYN) has been analyzed by 12 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 42% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dyne Therapeutics (DYN) Forecast

Analysts have given Dyne Therapeutics (DYN) a Buy based on their latest research and market trends.

According to 12 analysts, Dyne Therapeutics (DYN) has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dyne Therapeutics (DYN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.